United Therapeutics Corporation UTHR
Nov 4, 2026, 1:38 PM EST
- YTD
- +25.49%
- 1 year
- +39.82%
- Market cap
- 26.26B
- Revenue (ttm)
- 3.15B
- Profit margin
- 41.56%
- EPS (ttm)
- 28.21
- Shares out
- 42.89M
- P/E ratio
- 21.70
- Forward P/E
- 17.75
- YTD return
- +25.49%
- 1-year return
- +39.82%
- Volume
- 510.17K
- Avg volume
- 717.28K
- Open
- 585.00
- Previous close
- 601.32
- Day's range
- 578.28 – 614.23
- 52-week range
- 437.33 – 611.68
- Beta
- 0.48
- Analysts
- Buy
- Price target
- 670.93 (+9.7%)
- Earnings date
- Nov 4, 2026
1Y +161.99 (+36.20%)
Key statistics
- Enterprise value
- 22.91B
- PEG ratio
- 2.22
- Price / sales
- 8.18
- Price / book
- 4.01
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- -1.90%
- Free cash flow
- 557.14M
- Total cash
- 2.66B
- Total debt
- 0
- Return on equity
- 19.31%
- Short % of float
- 6.69%
- 50-day average
- 528.76
- 200-day average
- 532.16
Analyst view
Consensus: buy
- Target (low)
- 368.00
- Target (mean)
- 670.93
- Target (high)
- 850.00
- Strong buy3
- Buy8
- Hold3
- Sell1
- Strong sell0
Next earnings
Nov 4, 2026
Expected Nov 4, 2026. Consensus EPS estimate 6.34.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 4, 2026 | Sep 30, 2026 | 6.01 | — | — | — |
| Aug 5, 2026 | Jun 30, 2026 | 6.86 | 7.27 | +0.41 | +5.98% |
| May 6, 2026 | Mar 31, 2026 | 7.00 | 5.82 | -1.18 | -16.86% |
| Feb 25, 2026 | Dec 31, 2025 | 7.13 | 7.70 | +0.57 | +7.99% |
| Oct 29, 2025 | Sep 30, 2025 | 6.89 | 7.16 | +0.27 | +3.92% |
| Jul 30, 2025 | Jun 30, 2025 | 7.29 | 6.41 | -0.88 | -12.07% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 28, 2026 | JP Morgan | main | Overweight | Overweight |
| Oct 22, 2026 | RBC Capital | main | Outperform | Outperform |
| Oct 19, 2026 | Leerink Partners | main | Outperform | Outperform |
| Oct 8, 2026 | RBC Capital | main | Outperform | Outperform |
| Oct 7, 2026 | Morgan Stanley | main | Equal-Weight | Equal-Weight |
| Oct 1, 2026 | BTIG | up | Neutral | Buy |
About United Therapeutics Corporation
United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. It offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Nebulized Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, it is involved in developing RemunityPRO Pump and Ralinepag for the treatment of PAH;and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. Further, it provides preclinical products, including EVLP/CLES, for lung transplant; UKidney, UHeart, UThymoKidney, a development-stage gene-edited porcine kidneys and hearts for xenotransplantation; ULobe, for allogeneic regenerative medicine; ULung, for autologous regenerative medicine; IVIVA Kidney, for autologous regenerative medicine; miroliver, for allogeneic regenerative medicine; and mirokidney, for allogeneic regenerative medicine. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was founded in 1996 and is headquartered in Silver Spring, Maryland.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- United States
- Website
- unither.com
News
BTIG Maintains Buy on United Therapeutics, Raises Price Target to $768
United Therapeutics (UTHR) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
United Therapeutics (UTHR) Q3 Earnings Miss Estimates United Therapeutics Amends Agreement With Arena Pharmaceuticals, Pfizer Subsidiary, Eliminating All Royalty Obligations Under Its Exclusive License Agreement Related to Ralinepag for an Upfront Payment of $525M
United Therapeutics Announces Buydown of Ralinepag Royalty
United Therapeutics Corporation Reports Third Quarter 2026 Financial Results
ARM, McDonald's On Deck Wednesday As AI Demand, Consumer Spending Face Test
SpaceX Launch Customer Varda Says a Single Flight Could Help Make Medicine for Millions
SGIOY vs. UTHR: Which Stock Is the Better Value Option? JP Morgan Maintains Overweight on United Therapeutics, Lowers Price Target to $695
Your note
Sign in to keep a note on UTHR — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BENKOWITZ MICHAEL | President | Conversion of Exercise of derivative security | Mar 12, 2026 | 0 |
| CAUSEY CHRISTOPHER | Director | Sale | Mar 29, 2026 | 4,190 |
| EDGEMOND JAMES C. | Chief Financial Officer | Conversion of Exercise of derivative security | Jun 21, 2026 | 18,876 |
| GILTNER RICHARD A | Director | Conversion of Exercise of derivative security | Jul 8, 2026 | 21,884 |
| KURZWEIL RAYMOND C | Director | Conversion of Exercise of derivative security | Jul 8, 2026 | 13,320 |
| MAHON PAUL A | General Counsel | Sale | Sep 30, 2026 | 45,172 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 12.34% | 5,294,529 | 3.18B | Jun 29, 2026 |
| Avoro Capital Advisors LLC | 6.48% | 2,777,777 | 1.67B | Jun 29, 2026 |
| Vanguard Portfolio Management LLC | 4.48% | 1,919,429 | 1.15B | Jun 29, 2026 |
| Vanguard Capital Management LLC | 4.47% | 1,918,256 | 1.15B | Jun 29, 2026 |
| State Street Corporation | 4.43% | 1,898,064 | 1.14B | Jun 29, 2026 |
| Renaissance Technologies, LLC | 3.98% | 1,708,739 | 1.03B | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| iShares Trust-iShares Core S&P Mid-Cap ETF | 3.56% | 1,527,799 | 918.70M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.14% | 1,347,720 | 810.41M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 2.27% | 973,490 | 585.38M | Jun 29, 2026 |
| VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund | 1.68% | 719,385 | 432.58M | Jul 30, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 1.13% | 486,555 | 292.58M | Jun 29, 2026 |
| iShares Trust-iShares Biotechnology ETF | 0.75% | 323,432 | 194.49M | Sep 29, 2026 |
